By Bill Berkrot(Reuters) - An experimental once-weekly medicine for type 2 diabetes developed by Eli Lilly and Co proved as effective in lowering blood sugar as Victoza from Danish drugmaker Novo Nordisk in an eagerly anticipated late stage study.The Lilly drug, dulaglutide, achieved the primary goal of the 599-patient study by demonstrating so-called non-inferiority to the highest approved dose of Victoza after 26 weeks, according to initial results released by the company on Tuesday.
People with insulin resistance and type 2 diabetes are at higher risk of developing plaques associated with Alzheimer's, Japanese researchers said in a study out Wednesday.The research, published in the American Academy of Neurology, involved 135 people with an average age of 67 from Hisayama, Japan.The group was tested for blood sugar levels and followed over a period of 10-15 years to detect signs of Alzheimer's.
ByGlen S. Woods:Diabetes, a chronic disease that occurs when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces, affects 347 million people worldwide.
ByPsycho Analyst:Incretin drugs are a relatively new family of drugs for people with Type 2 diabetes. They work by elevating the level of GLP-1, an incretin hormone found in the gut, which has the effect of lowering blood sugar in the pancreas and curbing appetite in the brain. Some drugs in this family are a synthetic form of GLP-1. Others disable the enzyme that degrades GLP-1 so that its concentration rises to higher than normal levels.
By Peter Geschek:
The FDA has just approved Johnson & Johnson's (JNJ) Invokana (previously known as canagliflozin), a once-a-day pill to improve glycemic (blood sugar) control in adults with type 2 diabetes.
Hundreds of scientists sifting through genetic data from 122,000 people have quintupled the number of gene variants known to boost the risk of diabetes, a pair of studies released Sunday reported.A consortium of researchers first isolated 10 gene mutations that help determine the body's ability to regulate blood sugar and insulin levels, the key factors underlying type 2 diabetes.
The Burrill Report submits: The long road to approval for Mannkind's (MNKD) Afrezza inhaled insulin got a little longer March 15, as the FDA asked for more information to support its review of the drug. Afrezza is a powdered insulin for helping adult patients with type 1 and type 2 diabetes mellitus control high blood glucose, also known as hyperglycemia, which is a major cause of diabetes-related complications. An FDA decision on the drug was initially expected by January 16.